Inhibitor of KRAS gene mutation shows promise in lung, bowel and other solid tumors

(European Organisation for Research and Treatment of Cancer) New results from a clinical trial of a drug that targets a cancer-causing mutation in the KRAS gene have shown that it can shrink tumours and is well-tolerated by patients. In two presentations to the 32nd EORTC-NCI-AACR cancer symposium, researchers involved in the KRYSTAL-1 phase I/II clinical trial said that adagrasib (MRTX849) showed clinical activity and manageable adverse side effects in patients with non-small cell lung cancer, ...